Pasithea Therapeutics (KTTA) Competitors $0.72 0.00 (-0.07%) Closing price 03:58 PM EasternExtended Trading$0.71 -0.01 (-0.93%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. PMN, SONN, PASG, TAOX, SNYR, QTTB, NAII, CTXR, AYTU, and FNCHShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Promis Neurosciences (PMN), Sonnet BioTherapeutics (SONN), Passage Bio (PASG), Synaptogenix (TAOX), Synergy CHC (SNYR), Q32 Bio (QTTB), Natural Alternatives International (NAII), Citius Pharmaceuticals (CTXR), Aytu BioPharma (AYTU), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors Promis Neurosciences Sonnet BioTherapeutics Passage Bio Synaptogenix Synergy CHC Q32 Bio Natural Alternatives International Citius Pharmaceuticals Aytu BioPharma Finch Therapeutics Group Pasithea Therapeutics (NASDAQ:KTTA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability. Which has higher valuation & earnings, KTTA or PMN? Promis Neurosciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$13.90M-$7.55-0.10Promis NeurosciencesN/AN/A$2.78M-$0.21-2.18 Do institutionals & insiders have more ownership in KTTA or PMN? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 2.7% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is KTTA or PMN more profitable? Pasithea Therapeutics' return on equity of -88.60% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -88.60% -81.10% Promis Neurosciences N/A -266.69%-131.59% Does the media refer more to KTTA or PMN? In the previous week, Pasithea Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.00 beat Pasithea Therapeutics' score of -0.33 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Pasithea Therapeutics Neutral Promis Neurosciences Positive Do analysts prefer KTTA or PMN? Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 848.21%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, KTTA or PMN? Pasithea Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. SummaryPromis Neurosciences beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.36M$3.14B$5.81B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-0.1021.3676.8726.99Price / SalesN/A248.62449.2288.69Price / CashN/A45.4837.2260.63Price / Book0.079.6913.836.37Net Income-$13.90M-$52.92M$3.29B$271.46M7 Day Performance-8.78%1.44%0.94%2.34%1 Month Performance1.21%6.02%5.31%7.77%1 Year Performance-87.59%12.89%84.25%31.08% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics0.4557 of 5 stars$0.72-0.1%N/A-84.4%$5.36MN/A-0.103PMNPromis Neurosciences3.5509 of 5 stars$0.42-3.7%$4.33+929.3%-65.3%$22.64MN/A-2.005Positive NewsShort Interest ↓SONNSonnet BioTherapeutics1.9886 of 5 stars$3.12-5.2%$20.00+541.0%-7.2%$22.46M$20K0.0010High Trading VolumePASGPassage Bio4.1204 of 5 stars$7.00+1.2%$75.67+981.0%-51.7%$22.00MN/A-0.39130Positive NewsInsider TradeGap UpTAOXSynaptogenix0.1808 of 5 stars$6.24-0.5%N/AN/A$21.86MN/A-0.314Positive NewsSNYRSynergy CHC3.9925 of 5 stars$2.24-2.2%$10.00+346.4%N/A$21.62M$34.83M5.8940News CoverageGap UpQTTBQ32 Bio2.2057 of 5 stars$1.78+1.7%$12.17+583.5%-96.3%$21.35M$1.16M-0.4139NAIINatural Alternatives International1.4102 of 5 stars$3.34-2.2%N/A-53.1%$21.07M$113.80M-2.40290CTXRCitius Pharmaceuticals2.1658 of 5 stars$1.21-0.8%$53.00+4,280.2%-90.6%$20.76MN/A0.0020Short Interest ↑AYTUAytu BioPharma3.6854 of 5 stars$2.33+2.6%$10.00+329.2%-8.3%$20.38M$81M-3.24160News CoverageUpcoming EarningsHigh Trading VolumeFNCHFinch Therapeutics Group1.4088 of 5 stars$12.67-0.2%N/A+7.8%$20.35MN/A-1.44190Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies Promis Neurosciences Alternatives Sonnet BioTherapeutics Alternatives Passage Bio Alternatives Synaptogenix Alternatives Synergy CHC Alternatives Q32 Bio Alternatives Natural Alternatives International Alternatives Citius Pharmaceuticals Alternatives Aytu BioPharma Alternatives Finch Therapeutics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe Return of The KingGold has just surpassed the euro to become the world’s #2 reserve asset — a milestone that signals a massive s...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
